X

Trial Profile

A Phase I Study of Riluzole in Combination With mFOLFOX6/Bevacizumab in Patients With Metastatic Colorectal Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 21 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Oxaliplatin (Primary) ; Riluzole (Primary)
Indications Colorectal cancer
Focus Adverse reactions

Most Recent Events

20 Jan 2024 Results assessing safety of of riluzole in combination with mFOLFOX6 and bevacizumab in treating patients with metastatic colorectal cancer presented at the 2024 Gastrointestinal Cancers Symposium
02 May 2023 Status changed from recruiting to active, no longer recruiting.
14 Dec 2021 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com